Nasdaq
$0.9800▼ 0.69%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $42.2MShares out 43.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.8After-hours26.09.09 06:258-KKey event#●●●
Estrella Immunopharma, Inc.Bullish
Estrella Immunopharma has received a notification from Nasdaq for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days.…more
$0.9800-0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.26After-hours26.08.27 08:234Ownership
Estrella Immunopharma, Inc.
Insider Liu Cheng of Estrella Immunopharma, Inc. filed a Form 4 on August 26, 2026, reporting changes in beneficial ownership of securities as of August 25, 2026. This filing serves as an official record of the insider's equity position adjustments.…more
$0.9800-0.69%vs prev closeView filingShare - 8.26Overnight26.08.26 10:554Ownership
Estrella Immunopharma, Inc.
Insider Xu Jiandong of Estrella Immunopharma, Inc. reported a change in beneficial ownership of securities effective August 18, 2026. This filing serves as the official record of the insider's equity transaction in accordance with SEC Form 4 requirements.…more
$0.9800-0.69%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoOvernight26.10.22 15:10#●●●#●●●
Estrella Immunopharma Shares Surge Following Positive Clinical Trial Data…more
Estrella Immunopharma shares rallied after the company reported positive early-stage clinical data for its CD19-redirected T-cell therapy, EB103. Investors should remain cautious as these results are based on a small patient cohort and further clinical validation is required.…more
$0.9800-0.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.16Overnight26.10.16 15:48
●●●●●●●● ●●●●● ●●●●●●
Estrella's EB103 showed no treatment-related serious adverse events in the first patient dosed at the recommended Phase II level. The high-dose cohort also achieved a 100% complete response rate at the one-month mark.…more
$0.9800-0.69%vs prev closeShareBenzinga - 10.14After-hours26.10.15 05:16
●●●●●●●● ●●●●● ●●●●●●
Estrella Immunopharma has activated its fifth clinical site for the Phase 1/2 trial of EB103, targeting relapsed or refractory B-cell lymphoma. This expansion is expected to accelerate patient enrollment and the overall progress of the clinical study.…more
$0.9800-0.69%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report